Imfinzi Set to Become First Immunotherapy for Stomach Cancer Patients on NHS

Why It Matters

The decision gives thousands of UK stomach‑cancer patients earlier access to a therapy that meaningfully extends survival, while the streamlined NICE‑MHRA pathway demonstrates a new model for rapid adoption of high‑value oncology drugs, benefiting both patients and taxpayers.

Key Takeaways

• Imfinzi approved for resectable gastric and gastro‑oesophageal cancers in NHS
• Phase III MATTERHORN trial showed 22% death risk reduction vs chemo
• Three‑year survival rises to 69% with Imfinzi‑FLOT regimen
• NICE fast‑track recommendation delivered 17 days after marketing authorisation
• Imfinzi generated $6 billion in 2025, up 29% YoY

Pulse Analysis

Gastric and gastro‑oesophageal cancers remain a global health challenge, accounting for nearly one million new diagnoses each year and ranking as the fifth leading cause of cancer death. In the United Kingdom, about 7,000 cases are diagnosed annually, and long‑term survival rates are low, with only 16% of patients reaching a ten‑year horizon. Traditional chemotherapy offers limited durability, prompting clinicians to explore immunotherapy options that can harness the body’s own immune system to target malignant cells. Imfinzi’s entry into the NHS formulary marks a pivotal shift toward integrating checkpoint inhibitors into curative‑intent treatment pathways for resectable disease.

The Phase III MATTERHORN trial provided the clinical evidence that convinced NICE to act swiftly. Patients receiving Imfinzi alongside the FLOT regimen experienced a statistically significant improvement in event‑free survival and a 22% reduction in overall mortality risk compared with FLOT alone. The three‑year survival advantage—69% versus 62%—translates into thousands of additional life‑years for a disease historically plagued by rapid recurrence after surgery. Moreover, the NICE‑MHRA aligned pathway compressed the usual post‑authorisation lag to just 17 days, showcasing a regulatory model that could accelerate access to breakthrough oncology therapies across Europe.

Beyond the immediate patient impact, Imfinzi’s NHS adoption underscores broader market dynamics. The drug generated $6 billion in 2025, a 29% increase over the prior year, driven by expanding indications in bladder and lung cancer as well as now gastric cancer. Faster access pathways can improve health‑system efficiency by reducing downstream costs associated with disease progression, while also delivering value for taxpayers through negotiated pricing. As other manufacturers eye similar immuno‑oncology targets, the Imfinzi case may set a precedent for how high‑impact therapies are evaluated, priced, and rolled out in publicly funded health systems worldwide.